These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35774800)

  • 21. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.
    Russell MS; Thulasi Raman SN; Gravel C; Zhang W; Pfeifle A; Chen W; Van Domselaar G; Safronetz D; Johnston M; Sauve S; Wang L; Rosu-Myles M; Cao J; Li X
    Front Immunol; 2021; 12():747866. PubMed ID: 34603336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
    Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
    Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.
    Garg R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Hum Vaccin Immunother; 2017 Dec; 13(12):2894-2901. PubMed ID: 28825870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome.
    Xu J; Ding Y; Yang Y
    Viral Immunol; 2008 Dec; 21(4):483-9. PubMed ID: 19115938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.
    Blodörn K; Hägglund S; Fix J; Dubuquoy C; Makabi-Panzu B; Thom M; Karlsson P; Roque JL; Karlstam E; Pringle J; Eléouët JF; Riffault S; Taylor G; Valarcher JF
    PLoS One; 2014; 9(6):e100392. PubMed ID: 24945377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
    Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis.
    Bartholdy C; Olszewska W; Stryhn A; Thomsen AR; Openshaw PJM
    J Gen Virol; 2004 Oct; 85(Pt 10):3017-3026. PubMed ID: 15448365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
    Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
    Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Universal vaccine against respiratory syncytial virus A and B subtypes.
    Lee JY; Chang J
    PLoS One; 2017; 12(4):e0175384. PubMed ID: 28384263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease.
    Stevens WW; Sun J; Castillo JP; Braciale TJ
    Viral Immunol; 2009 Jul; 22(4):243-51. PubMed ID: 19594395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
    Taylor G; Thom M; Capone S; Pierantoni A; Guzman E; Herbert R; Scarselli E; Napolitano F; Giuliani A; Folgori A; Colloca S; Cortese R; Nicosia A; Vitelli A
    Sci Transl Med; 2015 Aug; 7(300):300ra127. PubMed ID: 26268314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cells contribute to enhanced respiratory disease after oil-in-water emulsion adjuvanted vaccination against respiratory syncytial virus and infection.
    Park Y; Kim KH; Lee Y; Lee YT; Kang SM; Ko EJ
    Hum Vaccin Immunother; 2021 Oct; 17(10):3806-3817. PubMed ID: 33877948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
    Rigter A; Widjaja I; Versantvoort H; Coenjaerts FE; van Roosmalen M; Leenhouts K; Rottier PJ; Haijema BJ; de Haan CA
    PLoS One; 2013; 8(8):e71072. PubMed ID: 23951084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
    Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
    J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
    Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.